239 related articles for article (PubMed ID: 24028772)
1. Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity.
van Bladel ER; Tuinenburg A; Roest M; de Groot PG; Schutgens RE
Haemophilia; 2014 Jan; 20(1):92-8. PubMed ID: 24028772
[TBL] [Abstract][Full Text] [Related]
2. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
3. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
[TBL] [Abstract][Full Text] [Related]
4. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
5. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
7. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
Kallas A; Talpsep T
Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
[TBL] [Abstract][Full Text] [Related]
9. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
[TBL] [Abstract][Full Text] [Related]
10. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling.
Mazurier C; Gaucher C; Jorieux S; Parquet-Gernez A; Goudemand M
Br J Haematol; 1990 Nov; 76(3):372-9. PubMed ID: 2124499
[TBL] [Abstract][Full Text] [Related]
12. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
14. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.
Peyvandi F; Mannucci PM; Valsecchi C; Pontiggia S; Farina C; Retzios AD
Am J Hematol; 2013 Oct; 88(10):895-8. PubMed ID: 23813910
[TBL] [Abstract][Full Text] [Related]
17. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
18. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
Lewis SJ; Stephens E; Florou G; Macartney NJ; Hathaway LS; Knipping J; Collins PW
Br J Haematol; 2007 Sep; 138(6):775-82. PubMed ID: 17672884
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
[TBL] [Abstract][Full Text] [Related]
20. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]